HYCALIEVA 2.5 mg contains Topotecan, a topoisomerase-I inhibitor belonging to the camptothecin class. It works by stabilizing the topoisomerase-I–DNA complex, causing DNA strand breaks and preventing DNA replication, leading to cancer cell death.

Topotecan is indicated for:

1. Ovarian Cancer
    – Metastatic or recurrent disease after platinum-based therapy

2. Small Cell Lung Cancer (SCLC)
    – Relapsed or refractory disease

3. Cervical Cancer
    – In combination with cisplatin

Common side effects:

•  Severe myelosuppression (neutropenia, thrombocytopenia, anemia)

•  Nausea, vomiting

•  Diarrhea

•  Fatigue

Other side effects:

•  Alopecia

•  Fever

Serious side effects:

•  Severe infections due to neutropenia

•  Interstitial lung disease (rare)

 Regular monitoring of CBC is mandatory before each cycle.

Dosage depends on indication and patient factors.

Common regimens:

•  1.5 mg/m²/day IV for 5 consecutive days

•  Cycle repeated every 21 days

2.5 mg vial allows accurate dose calculation.


NOTE: This medicine should be taken only under a doctor’s supervision.